Abstract: Inhibitors of glucosylceramide degradation, to pharmaceutical compositions containing same and to the use of same in the treatment of diseases of the motor units, such as amyotrophic lateral sclerosis.

Abstract: Disclosed herein are compositions and methods useful for the treatment or amelioration of various diseases, disorders, or conditions. Some aspects pertain to a composition comprising a testosterone source, an aromatase inhibitor, and an estriol source. Also presented herein is the surprising discovery that exposing a subject to the compositions disclosed herein can increase a subject's longevity, survival time, life span, and health span, as well as treat Alzheimer's disease.

Abstract: This application relates to various crystalline forms of (S)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide in its free form, as well as compositions, method of making and methods of using the same. In some embodiments the crystalline forms also contain water (“hydrates”). These materials are useful in the treatment of various autoimmune diseases, including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis and psoriasis.

Abstract: Compositions are provided for removing nail polish that include a co-mixture that consists of C2-C3 monoalcohol, glycerin, and a solvent selected from acetone, a C2-C4 alkyl acetate, and combinations thereof. The compositions are essentially free of water. The glycerin and the solvent are present in a glycerin to solvent weight ratio of at least 1.2. The concentration of C2-C3 monoalcohol is from 5% by weight to 50% by weight. If the solvent includes C2-C4 alkyl acetate, then the concentration of C2-C3 monoalcohol is from 15% by weight to 50% by weight and the glycerin and the solvent are present in a glycerin to solvent weight ratio of at least 2.0. The composition further includes a polyacrylamide.

Abstract: The present disclosure provides broad-spectrum carbapenem derivatives and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such derivatives and/or compositions.

Abstract: A herbicidal combination comprising at least two synthetic auxins, or at least two synthetic auxins with at least one ALS inhibitor, a composition comprising these combinations, a method of use of these combinations and a kit comprising the components of these combinations.

Abstract: The preparation and properties of crystalline polymorphs and solvates of 1-benzyl-8-methyl-1,4,8-triazaspiro-[4.5]-decan-2-one free base and of the mono- and dihydrochloride salts and solvates thereof are disclosed, as is an amorphous polymorph of the dihydrochloride. A pharmaceutical composition containing one or more polymorphs and a method of using that composition are also disclosed.

Abstract: An 5-(4,5-bis(4-chlorophenyl)-2-(4-methoxyphenyl)-1H-imidazol-1-yl)pentanoic compound, its synthesis, and its use as an antimicrobial agent.

Abstract: The disclosure is related to a meloxicam compositions, pharmaceutical preparations, preparation methods and use thereof. In one aspect of the invention, meloxicam compositions contain meloxicam and cosolvents. The cosolvents are mixed solvents including water and organic solvents. In another aspect of the invention, other compositions contain meloxicam, solvents, and pH regulators. The pH regulators include at least citric acid. The pharmaceutical compositions significantly enhance the solubility of meloxicam in liquid pharmaceutical preparations as well as stability. The meloxicam compositions can be directly used for intravenous injection administration to quickly reach effective therapeutic concentrations for post-operative analgesia.

Abstract: A 6?-(2-bromophenyl)-2?-ethoxy-3,4?-bipyridine-3?-carbonitrile as antioxidant compound, its synthesis, and its use as an antioxidant agent.

Abstract: The present disclosure relates to a method for preparing a transglucosylated steviol glycoside using a crude enzyme liquid of a Lactobacillus mali strain.

Abstract: A compound 3-(4,5-Diphenyl-2-(pyridin-3-yl)-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine, its synthesis, and its use as an anticancer agent.

Abstract: The present application includes an enantiomerically pure compound of Formula (R)-I or a salt and/or solvate thereof. Also included are compositions of the enantiomerically pure compound of Formula (R)-I as well as methods of using the compound of Formula (R)-I or composition thereof for treating, for example, disease, disorder or condition that benefits from psychotherapy. The present application also includes a composition comprising a non-racemic mixture a compound of Formula (R)-I, or a salt and/or solvate thereof, and (S)-I, or a salt and/or solvate thereof: wherein (R)-I, or a salt and/or solvate thereof, is present in the composition in a greater amount by enantiomeric equivalents, relative to (S)-I, or a salt and/or solvate thereof and uses thereof. Further included are process preparing a compound of Formula (R)-I or (S)-I.

Abstract: The present invention relates to naltrexone or an analogue thereof, wherein the analogue is methylnaltrexone, naloxone, nalmefene and nalorphine and vitamin D or an active metabolite, or a pharmaceutically acceptable salt of either for separate, sequential or simultaneous administration, for use in the therapy of an autoimmune disease.

Abstract: The present invention includes a method of treating a bone disease caused by a intracellular protein trafficking defect comprising: identifying a subject having the bone disease caused by the intracellular protein trafficking defect in a membrane bound transcription factor peptidase, site 1 (MBTPS1) gene; and providing the subject with an effective amount of a composition that bypasses or corrects a defect in MBTPS1 gene expression, gene splicing, or corrects protein trafficking defects in the endoplasmic reticulum and to the lysosome.

Abstract: A method for treating depression in a human subject, which comprises administering for a first time period a fasting mimicking diet (FMD) component providing less than 50% of the normal calorie intake of the subject with both protein restriction and sugar restriction; and administering for a second time period a re-feeding diet component that provides 60-100% of the normal calorie intake of the subject; the fasting mimicking diet component and the re-feeding diet component are administered for multiple cycles, and the subject undergoes a psychotherapeutic treatment for the whole duration of the multiple cycles.

Abstract: The present disclosure relates generally to compounds, of Formula I: Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

Abstract: ZnCl2 co-crystal of racemic-(±)-blarcamesine hydrochloride of formula 2a, ZnCl2 co-crystal of (S)-(?)-blarcamesine hydrochloride of formula 2b and ZnCl2 co-crystal of (R)-(+)-blarcamesine hydrochloride of formula 2c, processes for preparation thereof and pharmaceutical preparation thereof and methods of treating neurodegenerative, neurodevelopmental diseases such as Alzheimer's disease, Parkinson's disease dementia and/or Rett syndrome.

Abstract: Disclosed herein are antimicrobial compounds, compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use a therapeutic agents.

Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in methods of preventing pancreatic beta cell degeneration or methods of treating a disorder associated with pancreatic beta cell degeneration, such as type I diabetes.